Since clinical FTO inhibitors are being developed for the treatment of obesity and cancer, this study provides the preclinical data to support future studies evaluating the efficacy and safety of clinical FTO inhibitors as radiosensitizers. The gene discussed is FTO; the disease is obesity due to melanocortin 4 receptor deficiency.